To identify the rate of postoperative complications in patients who require surgical reconstruction for ketamine-induced urinary tract dysfunction and to identify any predictors for poor postoperative outcome with subsequent management strategies.
Introduction
Ketamine hydrochloride is a glutamatergic N-methyl-Daspartate antagonist. Following its discovery in 1960 as an analgesic and sedative agent, ketamine has become a popular recreational drug because of its well-recognised dissociative effect causing powerful hallucinations and out-of-body experiences. Its non-medical use has been illegal in the UK since it was classified as a Class C drug in 2006 [1] .
Also known as 'K', 'Special K' and 'Dorothy', the use of ketamine as a street drug has increased over the years due to a common misperception that it is less harmful with a lower addictive potential than other drugs, such as heroin, due to its short-acting nature [2, 3] . Combined with its relatively low cost and ease of accessibility (street value of £20/g compared with £50/g for cocaine and £45/g for heroin) [4] , recognition of ketamine-associated pathology is on the rise.
The recent British Crime Survey reports an increase from 0.40% in 2007 to 0.60% in 2014 amongst those in the age group of 16-59 years. For even younger adults aged 16-24 years, there was a significant increase in the use of ketamine between 2012-2013 and 2013-2014 from 0.80 to 1.8% [3] .
Long-term neuro-psychological consequences have been well-recognised including: memory impairment, persistent dissociative, depressive and delusional thinking [5] . Other systemic effects have also been noted including gastric and hepatic dysfunction [5] and following two published series in 2007 from Ontario and Hong Kong, ketamine-induced urinary tract dysfunction has become an increasingly recognised entity [2, 6] .
The first series from Canada included nine patients presenting with a spectrum of debilitating LUTS including dysuria, frequency, urgency/urge incontinence, and haematuria. The most consistent symptom was profound bladder pain [6] . About 20-30% of long-term ketamine abusers report such symptoms, which can be collectively referred to as ketamine-induced cystitis [1] .
Although presenting with lower urinary tract dysfunction, there is now evidence of upper urinary tract involvement with peri-ureteric (retroperitoneal) inflammation or direct renal damage resulting in renal impairment [2] .
Assessment of ketamine cystitis (KC) is not standardised. It is important to exclude other pathology and thus baseline investigation should include frequency/volume charts, urine analysis and ultrasonography (US). In patients with severe symptoms, hydronephrosis and impaired renal function may be found [6, 7] . In such patients CT typically reveals marked thickening of the bladder wall and perivesicular stranding consistent with severe inflammation. We perform video-urodynamics and mercapto-acetyltriglycine (MAG3) renography in these patients to assess bladder function (compliance) and renal drainage. Common cystoscopic findings are severe ulcerative cystitis and a marked reduction in bladder capacity with histology showing pan-vesical (eosinophilic) inflammation and fibrosis [8] .
To our knowledge, we report the largest UK series focussing on the outcomes of the surgical management of these patients. The aim of the present study was to identify the rate of postoperative complications in patients who have undergone surgical reconstruction for ketamine-induced urinary tract dysfunction and to identify any predictors for poor postoperative outcome with subsequent management strategies.
Patients and Methods
We reviewed our prospectively acquired database of all patients with ketamine-induced urinary tract disease. Patients referred between 2007 and 2017 were included.
All patients underwent a detailed history. Symptoms were assessed using bladder diaries and frequency/volume charts. Recreational drug history was explored. If disclosed, the type of drug, mode of ingestion, dosage, and duration were documented. Patients were encouraged to seek expert support for cessation of ketamine use.
Blood or urine tests for ketamine levels prior to intervention were not routinely performed. Urine microscopy and culture were performed in all patients to assess for evidence of a concurrent UTI. Baseline renal and liver functions were also tested.
Ultrasonography and if indicated CT urography of the urinary tract were performed to check for hydronephrosis, bladder wall thickening, and evidence of ureteric strictures. A video cystometrogram (VCMG) was performed in patients with severe symptoms (frequency), and/or dilated upper tracts to check for bladder compliance loss. MAG3 renography was performed in those with evidence of ureteric obstruction on CT urogram or poorly compliant bladders.
Cysto-urethroscopy under general anaesthetic was performed to allow for accurate evaluation of bladder capacity with biopsy if indicated.
Patients with no evidence of renal failure or ureteric obstruction were managed medically according to their symptoms. Anti-cholingerics AE b 3 -adrenoceptor agonists were commenced for those with overactive bladder symptoms and onabotulinum injections for those with medically refractory symptoms. Carefully selected analgesic regimens were prescribed for those with significant bladder pain.
For those with refractory symptoms (generally functional capacity <200 mL), significant compliance loss (compliance pressures 40 cmH 2 0 or worse) and/or upper tract compromise, patients were appropriately counselled for surgical reconstruction including augmentation cystoplasty, cystectomy and orthotopic or heterotopic neobladder, urinary diversion and/or ureteric re-implantation depending on the degree of bladder involvement, ureteric involvement and bladder capacity. Patients were advised to abstain from ketamine use for a minimum of 6 months prior to any surgical intervention. All cases were assessed via a multi-disciplinary process.
Augmentation enterocystoplasty was performed using a 30-40 cm segment of terminal ileum; subsequently detubularised to form a 'U'-shaped double clam. In cases where cystectomy was necessary, the bladder was removed leaving the bladder neck intact. Either a Studer-type or an ileocaecal neobladder was performed. The ureters were implanted into an ileal chimney using a Wallace technique. If there were documented ureteric strictures the ileal chute could be extended, the ureters divided at a point where they appeared healthy. Wallace or Bricker uretero-ileal anastomoses were calibrated with 8-10 F catheters.
Results
A total of 44 patients, with a mean (range) age of 31 (23-55) years were referred with KC; 68% (30/44) were male. Estimated mean (range) ketamine dose at maximum use was 8.9 (1-67) g over a mean (range) duration of declared use of 79 (2-192) months. The mean (range) follow-up was 37 (0-101) months and two patients (5%) were lost to follow-up.
Patients presented with bladder pain and severe LUTS; nine (20%) had visible haematuria. Three patients (6.8%) had a significantly impaired GFR (<35 mL/min/1.73 m 2 ) on referral. One of these three patients with a GFR of 18 mL/min/1.73 m 2 had their obstructive uropathy managed acutely with bilateral nephrostomy drainage. All three patients were committed to reconstructive intervention.
Overall, 28 patients had CT imaging. Of those, 82% (23/28) of patients had normal upper tracts on CT urogram; one had incidental bilateral renal stones and was referred to endourology for further input, and 14% (4 of 28) had bilateral hydronephrosis associated with a small thick-walled bladder, of which one (3.6%) had concomitant ureteric strictures. MAG3 renography showed delayed drainage in 16% (7 of 44) of patients and 20% (9 of 44) also underwent VCMG. The procedure was abandoned in one of these patients for pain. All nine patients had markedly reduced functional capacity with evidence of significant compliance loss (Fig. 1) . One patient had concomitant VUR (Fig. 2 ).
All patients were booked for cysto-urethroscopy and evaluation of bladder capacity, and 81.8% (36/44) were found to have reduced cystoscopic and functional bladder capacity of <300 mL (mean 196, range 25-550 mL). In all, 52% (23/44) of patients had a biopsy; all confirming an eosinophilic inflammatory infiltrate with perivesical fibrosis.
Overall, 66% (29/44) of patients were treated conservatively with a combination of anti-cholinergics, b 3 -adrenoceptor agonists and/or analgesics. One of the 29 patients was treated with oral pentosan polysulphate sodium with good effect. Two of the 29 patients underwent urethral dilatation for urethral strictures. Four of the 29 patients underwent repeated intra-detrusor onabotulinum toxin injection with minimal subjective symptom relief, with two of these patients proceeding to have major reconstruction.
In all, 14 patients underwent major reconstruction. One patient elected to have an ileal conduit for bladder pain. Seven patients underwent cystectomy plus neobladder, of which four had a Mitrofanoff channel and one underwent bilateral ureteric re-implantation. The remaining six patients underwent augmentation cystoplasty, of which four had a Mitrofanoff channel and two had concurrent ureteric re-implantation. Outcomes are detailed in Table 1 . Of the 14 20 ml 40 ml 60 ml 80 ml 100 ml 120 ml 140 ml 160 ml 180 ml200 ml 220 ml 240 ml260 ml 280 ml 300 ml patients, 10 had one or more postoperative complication(s) requiring intervention, and three of these 10 had subsequent further complications. Complications included two ureteroileal leaks, three ureteric strictures, one ileo-colonic anastomotic leak, one adhesional small bowel obstruction with ischaemia, two chronic renal failures, one high pressure detrusor overactivity (DO), and one urosepsis.
Discussion
There is limited literature to support how to manage patients with KC. The time of onset of LUTS can vary from a few days to a few years. However, the precise dose and timeframe required to cause bladder pain and other LUTS leading to irreversible scarring and damage remains unclear [9] .
Most patients with KC are managed conservatively, or with minimally invasive surgical intervention. Urinary tract reconstruction is reserved for those with refractory symptoms, contracted bladders or upper tract compromise. In the present study, ketamine abusers appeared to have a significantly higher rate of postoperative complications when compared with patients who underwent reconstructive surgery for other benign disease (congenital anomalies, neurogenic disease, intractable incontinence, and interstitial cystitis/bladder pain syndrome -IC/BPS). In all, 10 of 14 patients in our present series had one or more postoperative complication(s) requiring surgical/radiological intervention, of which three had further complications. Four of the 14 patients that underwent surgical intervention developed new onset ureteric obstruction after the primary surgery, despite normal preoperative CT urograms. These patients required subsequent ureteric re-implantation.
Evaluation should be extensive. Urine analysis, renal and liver function tests should be performed. Urine cultures were typically negative as in our present series, although an occasional contaminated growth or sterile pyuria may be present [7, 10] . Impaired renal function is associated with chronic misuse and deranged liver function tests are not uncommon due to ketamine-induced hepatic dysfunction [11] .
Radiographic investigations must include US of the upper tracts to check for hydronephrosis, CT urography to check for ureteric disease, and VCMG to check bladder capacity and compliance pressures [8] .
Cystoscopy and histology shows ulceration associated with a mixed inflammatory infiltrate, rich in eosinophils and reactive urothelium [7, 8] . In our present series, all patients had an eosinophilic infiltrate; however, this is not a finding specific to KC and can be found in the bladder in a variety of conditions. In addition to this inflammatory infiltrate, there is also marked urothelial atypia, which has been previously misdiagnosed as carcinoma in situ [12] .
The recommended anaesthetic dose of ketamine is 0.5-2 mg/kg; however, recreational users develop tolerance with continued use and can therefore use up to 6 g/day [12] . Most ketamine abusers (78.9%) will display features of physiological dependence after regular use for 1 year, with almost half of these patients (53.3%) reporting withdrawal symptoms on cessation [13] . Many patients with KC become dependent on ketamine to reduce their bladder pain, resulting in cyclical dependency. Involvement of chronic pain teams is therefore essential to help develop alternate strategies to optimise pain control. Buprenorphine patches with co-codamol and amitriptyline have been proposed to minimise ketamine dependence [8] .
Minimally invasive approaches have included cystodistension, urethral dilatation, oral pentosan polysulphate (Elmiron) and intravesical instillations of hyaluronic acid (Cystistat), using the same principle applied to those with other inflammatory cystitis conditions [6] . Intra-detrusor injections of onabotulinum toxin have also been tried [8] but were ineffective in the two patients in our present series, presumably due to loss of the bladder wall elasticity replaced by fibrotic contracture. Options for surgical reconstruction include supratrigonal cystectomy with enterocystoplasty, total cystectomy and orthotopic neobladder formation, heterotopic neobladder with Mitrofanoff or urinary diversion with or without cystectomy. In 81.8% (36/44) of the present patients, bladder capacity was significantly reduced (<300 mL). For this group of patients, a supratrigonal cystectomy with enterocystoplasty is a suitable option. The aim of this procedure is to increase bladder capacity and improve compliance to minimise upper tract damage [14] . Supratrigonal substitution avoids ureteric re-implantation and anastomotic leak/stricture, allowing for spontaneous voiding by preserving the autonomic innervation to the bladder neck [15] . The complication rate of this procedure is reasonably low. In a series on the treatment of refractory IC/BPS, less than half of these patients developed complications (37%); two developed mild reflux and five required intermittent self-catheterisation [16] . Other complications of this procedure include recurrent infections and on-going pain [17] . As expected, those with smaller bladder capacities had better symptom resolution [18] .
For those with small fibrosed bladders and significant bladder pain, total cystectomy is necessary. These patients must be carefully selected, as cystectomy for benign disease has a 30-day complication rate up to 73% [19, 20] . In oncological series, where patients are generally older and have significant co-morbidities, postoperative cardiac complications and venous thrombo-emboli are common. In this younger cohort co-morbid status is a much lesser risk. In oncological series, anastomotic leaks and uretero-enteric strictures are reported in up to 5 and 12% of patients, respectively [21, 22] .
Urinary diversion without cystectomy can be performed in patients with KC. Supravesical diversion without cystectomy can be reversed and therefore may be the treatment of choice in defunctioning the bladder temporarily. It is routinely performed for non-malignant conditions including neurogenic bladders and intractable incontinence [23] . Although performing a synchronous cystectomy carries a higher risk of morbidity, leaving behind a defunctioned bladder can result in complication rates as high as 60%, including pyocystis, persistent haematuria, chronic pain and very occasionally malignancy [12, [24] [25] [26] . Such approaches have been successful in managing patients with IC/BPS. Outcomes are measured objectively by functional bladder capacity and voiding frequencies and subjectively using questionnaires to show improvement in pain and quality of life [27] .
Akin to IC/BPS, similar management strategies have been used to treat patients with KC. Chu et al. [2] published their largest series of 59 patients in 2008. Only one of these patients underwent reconstructive surgery in the form of an augmentation enterocystoplasty who had significant postoperative complications requiring an anastomotic ureteroplasty for a unilateral short segment ureteric stricture due to ongoing ketamine abuse. Both Chung et al. [14] and Jhang et al. [28] have reported on 14 and 28 patients, respectively, all of whom underwent augmentation enterocystoplasty to manage KC, with no significant peri-or postoperative complications. The reasons why higher rates of peri-and postoperative complications were seen in our present series are unclear. Some of our present patients seem to have had much more extensive inflammatory disease extending up the ureters retroperitoneally, and requiring more extensive reconstruction than that reported by Chu et al. [2] and Chung et al. [14] . This may reflect more severe, pan-urothelial retroperitoneal toxicity, which may have been a result of higher doses and/or more prolonged ketamine exposure.
Increasing ketamine dose and exposure time results in progressive microvascular damage, tissue fibrosis, and inflammatory change [29] . High concentration of the drug and its metabolites in the urine cause direct urothelial toxicity, resulting in a chronic submucosal inflammatory response. Elevated erythrocyte sedimentation rate (ESR) and Complement 3 (C3)/Complement 4 (C4) suggests an underlying autoimmune reaction to the bladder urothelium and submucosa resulting in autoimmune-mediated vascular congestion, submucosal oedema and scarring [7] . This replacement of elastic connective tissue and muscle fibres with fibrosis causes a reduction in bladder capacity with secondary high-pressure compliance loss. IgE-mediated or nitric oxide synthase (NOS)-cyclooxygenase (COX)-mediated inflammation has also been shown to cause collagen accumulation with fibrosis [8] . Ketamine and its metabolites have also been found to disrupt the bladder epithelial barrier resulting in increased permeability and leakage of urinary potassium and other irritative agents resulting in widespread pan-cystitis. Decreased levels of E-cadherin expression, a key molecule in maintaining bladder barrier function is also observed [30, 31] . Microvascular damage leads to bladder wall ischaemia and is thought to be the central cause of bladder pain on filling [32, 33] . Ketamine can also cause acute papillary necrosis, with migration of this sloughed papilla into the ureters causing complete ureteric obstruction [34] . In mice injected with ketamine, mononuclear infiltration extends throughout the entire urinary tract from the glomeruli, ureters to bladder causing a pan-urothelial inflammation [35, 36] .
Pan-urothelial inflammation with ischaemia may explain why our present patients had higher rates of postoperative complications, compared with our experience of reconstruction in patients with other aetiologies.
Conclusion
Urinary tract reconstruction in patients with severe KC is a major undertaking with a high risk of perioperative morbidity and long-term complications. High dosage and prolonged exposure to ketamine and its metabolites results in inflammatory changes, with microvascular damage, ischaemia and fibrosis. Although specific predictive factors for long-term outcome were not identified surgical intervention was reserved for those with the most severe compromise on functional assessment and cross-sectional imaging. It is presumed that this pan-urothelial damage causes tissue friability and compromised blood supply creating a perfect medium for anastomotic leaks and healing complications. In view of this, reconstructive surgery should be reserved for those with end-stage disease, renal impairment and/or intractable symptoms. Ketamine cessation is imperative as continued drug use will increase the risk of complications and disease recurrence.
